

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b><i>Complete if Known</i></b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/666,866-Conf. #6806
				Filing Date	September 19, 2003
				First Named Inventor	Andrew Segal
				Art Unit	1648
				Examiner Name	B. P. Blumel
Sheet	1	of	3	Attorney Docket Number	

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA**	WO-99/61051	12-02-1999			
	BB**	CA 2,375,619		Bublot M. et. al.		

Examiner Signature	Date Considered	
-----------------------	--------------------	--

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
				Application Number	10/666,866-Conf. #6806
				Filing Date	September 19, 2003
				First Named Inventor	Andrew Segal
				Art Unit	1648
				Examiner Name	B. P. Blumel
Sheet	2	of	3	Attorney Docket Number	85849DIV5(308597)
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	CA**	Burbage et al., Ricin Fusion Targeted To The Human Granulocyte-Macrophage Colony Stimulating Factor Receptor is Selectively Toxic to Acute Myeloid Leukemia Cells. Leukemia Research 1997, Vol. 21, No. 7, pages 681-690			
	CB**	Batova, et al., The CHI14, 18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro. Clin Cancer Res. 1999 Dec; 5(12): 4259-63			
	CC**	Babai, I et al., A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. Vaccine Characterization and Efficacy Study in mice. Vaccine 1999 Mar 5; 17(9-10); 1223-38			
	CD**	Babai, I et al., A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. Vaccine Characterization and Efficacy Study in mice. Vaccine 1999 Mar 5; 17(9-10); 1239-50			
	CE**	Babai, et al., A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains. Vaccine, Nov 12, 2001, Vol. 20, Issues 3-4 p. 505-515			
	CF**	Berzofsky et al., Progress on new vaccine strategies for the immunotherapy and prevention of cancer. The Journal of Clinical Investigation. June 2—4, Vol. 113, No. 11, 151-1525			
	CG**	Barker E., et al., Effect of a Chimeric Anti-Ganglioside G <sub>D2</sub> Antibody on Cell-mediated Lysis of Human Neuroblastoma Cells. Cancer Research (1991) 51; 144-149			
	CH**	Cantrell, et al., Cloning, sequence, and expression of a human granulocute/machorphage colony-stimulating factor (bone marrow colong assay/cDNA closing/yeast expression). PNAS 1985, VOL 82, pages 6250-6254			
	CI**	Chen T.T. et al., Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J. Immunol. 1994 Nov 15;153 (10); 4775-87			
	CJ**	Deliyannis, G. et al., A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge. PNAS 2000 (12):6676-6680			
	CK**	Erbe, et al., P-and E-Selectin Use Common Sites for Carbohydrate Ligand Recognition and Cell Adhesion. The Journal of Cell Biology 1993; Vol. 120, No. 5; pages 1227-1235			
	CL**	Faulkner et al., Influenza hemagglutinin peptides fused to interferon gamma and encapsulated in liposomes protects mice against influenza infection. Vaccine, February 14, 2003, Vol. 21, 932-939			
	CM**	Frankel A., et al., IL2-Ricin Fusion Toxin Is selectively Cytotoxic in Vitro to IL2 Receptors-Bearing Tumor Cells, Bioconjugate chem. 1995(6); 666-672			
	CN**	Galili et al., Cutting edge communication: Preparation of autologous leukemia and lymphoma vaccines expressing alpha GAL epitopes. Journal of Hematology and Stem Cell Research, 2001, Vol. 10., 501-511			
	CO**	Gillies, SD et al., Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-Ganglioside GD2 Antibody" Hybridoma, 1991;10(3):347-356			
	CP**	Gillies, DS et al., Antibody-targeted interleukin 2 stimulates T-cell kiling of autologous tumor cells, Proc. Natl. Acad. Sci. USA 1992; 89:1428-1432			

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b><i>Complete if Known</i></b>	
				Application Number	10/666,866-Conf. #6806
				Filing Date	September 19, 2003
				First Named Inventor	Andrew Segal
				Art Unit	1648
				Examiner Name	B. P. Blumel
Sheet	3	of	3	Attorney Docket Number	
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	CQ**	Guillet, et al., Functionally active fusion protein of the novel composite cytokine CLC/soluble CNTF receptor. European Journal of Biochemistry, 2002, Vol. 269, pages 1932-1941			
	CR**	Masuda et al., Substitution of amino acid residue in influenza A virus hemagglutinin affects recognition of sialyl-oligosaccharides containing N-glycolylneurameric acid. FEBS Letters, 1999, Vol. 464, p. 71-74			
	CS**	Nobusawa et al., Comparison of complete amino acid sequences and receptor-binding properties among 13 stereotypes of hemagglutinin of influenza A viruses. Virology 1991, Vol. 182, No. 2 pages 475-485			
	CT**	operschall, et al., Enhanced protection against viral infection by co-administration of plasmid DNA coding for viral antigen and cytokines in mice., Journal of Clinical Virology 1999, Vol. 13, pages 17-27			
	CU**	Robinson, et al., Optimizing the stability of single-chain proteins by linker length and composition mutagenesis. Proceedings of the National Academy of Sciences of the United States of America, 1998, Vol. 95, pages 5929-5934			
	CV**	Rodriguez, D et al. A human immunodeficiency virus type 1 Env-granulocyte-macrophage colony-stimulating factor fusion protein enhances the cellular immune response to ENV in a vaccinia virus-based vaccine. J. Gen. Virol. 1999 Jan; 80 (pt1):217-23			
	CW**	Shao, et al., Anchor-Chain Molecular system for orientation control in enzyme immobilization. Bioconjug., Chem. 2000, Vol. 11 pages 822-826			
	CX**	Yu, et al, Cancer Vaccines:Progress reveals new complexities. The Journal of Clinical Investigation. August 2, Vol. 110, No. 3 289-294			
	CY**	Varki, Review: Selectin Ligands, 1994 PNAS, Vol. 91, pages 7390-7397			
	CZ**	International Search Report for International Publication No. WO/018698, Mailed June 7, 2007.			
	CA1**	Scholler, et al., CD83 is a Sialic Acid-Bearing Ig-like Lectin (Siglec) Adhesion Receptor that Binds Monocytes and a Subset of Activated CD8 T Cells. Journal of Immunology 2001, Vol. 166, p. 3865-3872			
	CB2**	Worthman, et al., Enhanced protective antibody responses to PspA after intranasal or subcutaneous injections of PspA genetically fused to granulocyte-macrophage colony-stimulating factor or interleukin-2. Infection and Immunity, 1998, Vol. 66, No. 4 p. 1513-20			
	CC2**	operschall E, et al. Mechanism of protection against influenza A virus by DNA vaccine encoding the hemagglutinin gene. Intervirology. 2000;43(4-6):322-30			
	CD2**	Faulkner L., et al., IL-2 linked to a peptide from influenza hemagglutinin enhances T cell activation by affecting the antigen-presenting function of bone marrow-derived dendritic cells, International Immunology 2001, 13(6), pages 713-721			
Examiner Signature				Date Considered	

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup>CITE NO.: Those document(s) which are marked with an double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.